JP2020536903A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536903A5 JP2020536903A5 JP2020520290A JP2020520290A JP2020536903A5 JP 2020536903 A5 JP2020536903 A5 JP 2020536903A5 JP 2020520290 A JP2020520290 A JP 2020520290A JP 2020520290 A JP2020520290 A JP 2020520290A JP 2020536903 A5 JP2020536903 A5 JP 2020536903A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- prostate cancer
- castration
- pharmaceutical composition
- prednisone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 74
- 238000009472 formulation Methods 0.000 claims description 58
- 239000000203 mixture Substances 0.000 claims description 58
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 50
- 206010060862 Prostate cancer Diseases 0.000 claims description 45
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 45
- 230000001394 metastastic effect Effects 0.000 claims description 45
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 45
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 36
- 229960004618 prednisone Drugs 0.000 claims description 36
- 239000003098 androgen Substances 0.000 claims description 25
- 238000002560 therapeutic procedure Methods 0.000 claims description 18
- 230000004083 survival effect Effects 0.000 claims description 15
- 238000002648 combination therapy Methods 0.000 claims description 14
- 241000282412 Homo Species 0.000 claims description 8
- 238000010317 ablation therapy Methods 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 230000005713 exacerbation Effects 0.000 claims description 7
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 108010069236 Goserelin Proteins 0.000 claims description 2
- 108010000817 Leuprolide Proteins 0.000 claims description 2
- 238000002679 ablation Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229960003690 goserelin acetate Drugs 0.000 claims description 2
- 229960003911 histrelin acetate Drugs 0.000 claims description 2
- BKEMVGVBBDMHKL-VYFXDUNUSA-N histrelin acetate Chemical compound CC(O)=O.CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 BKEMVGVBBDMHKL-VYFXDUNUSA-N 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 2
- 229960004338 leuprorelin Drugs 0.000 claims description 2
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 claims description 2
- 238000011474 orchiectomy Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 32
- 229960004103 abiraterone acetate Drugs 0.000 claims 2
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 claims 2
- 239000013583 drug formulation Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570781P | 2017-10-11 | 2017-10-11 | |
| US62/570,781 | 2017-10-11 | ||
| PCT/US2018/017438 WO2019074536A1 (en) | 2017-10-11 | 2018-02-08 | METHODS OF TREATING PROSTATE CANCER BY ADMINISTERING ABIRATERONE ACETATE AND PREDNISONE WITH ANDROGENIC SEPARATION THERAPY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020536903A JP2020536903A (ja) | 2020-12-17 |
| JP2020536903A5 true JP2020536903A5 (https=) | 2021-03-11 |
Family
ID=61283312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520290A Pending JP2020536903A (ja) | 2017-10-11 | 2018-02-08 | アンドロゲン除去療法と共に酢酸アビラテロン及びプレドニゾンを投与することにより前立腺癌を治療する方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20190105332A1 (https=) |
| EP (1) | EP3694604A1 (https=) |
| JP (1) | JP2020536903A (https=) |
| KR (1) | KR20200068689A (https=) |
| CN (1) | CN111542373A (https=) |
| AU (1) | AU2018347804A1 (https=) |
| BR (1) | BR112020007090A2 (https=) |
| CA (1) | CA3077678A1 (https=) |
| EA (1) | EA202090916A1 (https=) |
| IL (1) | IL273826A (https=) |
| JO (1) | JOP20200072A1 (https=) |
| MA (1) | MA50341A (https=) |
| MX (1) | MX2020003830A (https=) |
| PH (1) | PH12020550151A1 (https=) |
| UA (1) | UA124865C2 (https=) |
| WO (1) | WO2019074536A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019001398A2 (pt) | 2016-07-29 | 2019-05-07 | Janssen Pharmaceutica Nv | métodos para tratamento de câncer de próstata |
| AU2018351714A1 (en) | 2017-10-16 | 2020-04-30 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
| UY39201A (es) * | 2020-05-08 | 2021-11-30 | Janssen Pharmaceutica Nv | Tratamientos del cáncer de próstata con combinaciones de acetato de abiraterona y niraparib |
| CN117120034A (zh) * | 2021-02-15 | 2023-11-24 | 普洛佩拉治疗公司 | 阿比特龙前药 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102898495B (zh) * | 2012-11-12 | 2014-11-26 | 浙江神洲药业有限公司 | 醋酸阿比特龙酯的制备方法 |
-
2018
- 2018-02-08 EP EP18707472.9A patent/EP3694604A1/en not_active Withdrawn
- 2018-02-08 US US15/891,974 patent/US20190105332A1/en not_active Abandoned
- 2018-02-08 MX MX2020003830A patent/MX2020003830A/es unknown
- 2018-02-08 CN CN201880079993.2A patent/CN111542373A/zh active Pending
- 2018-02-08 AU AU2018347804A patent/AU2018347804A1/en not_active Abandoned
- 2018-02-08 MA MA050341A patent/MA50341A/fr unknown
- 2018-02-08 JP JP2020520290A patent/JP2020536903A/ja active Pending
- 2018-02-08 CA CA3077678A patent/CA3077678A1/en active Pending
- 2018-02-08 JO JOP/2020/0072A patent/JOP20200072A1/ar unknown
- 2018-02-08 WO PCT/US2018/017438 patent/WO2019074536A1/en not_active Ceased
- 2018-02-08 UA UAA202002743A patent/UA124865C2/uk unknown
- 2018-02-08 BR BR112020007090-4A patent/BR112020007090A2/pt not_active IP Right Cessation
- 2018-02-08 EA EA202090916A patent/EA202090916A1/ru unknown
- 2018-02-08 KR KR1020207012842A patent/KR20200068689A/ko not_active Ceased
-
2019
- 2019-11-05 US US16/674,323 patent/US20200069704A1/en not_active Abandoned
-
2020
- 2020-03-26 PH PH12020550151A patent/PH12020550151A1/en unknown
- 2020-04-06 IL IL273826A patent/IL273826A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Windle et al. | Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer | |
| Reid | Efficacy, effectiveness and side effects of medications used to prevent fractures | |
| TWI729394B (zh) | 雄性激素受體調節劑及其用途 | |
| Kia et al. | Comparative efficacy of topical curcumin and triamcinolone for oral lichen planus: a randomized, controlled clinical trial | |
| Ramírez et al. | New non-bisphosphonate drugs that produce osteonecrosis of the jaws | |
| JP2020536903A5 (https=) | ||
| Van Dodewaard-De Jong et al. | New treatment options for patients with metastatic prostate cancer: what is the optimal sequence? | |
| Pincus et al. | Clinical trials documenting the efficacy of low-dose glucocorticoids in rheumatoid arthritis | |
| JP2020503269A5 (https=) | ||
| Biancone et al. | Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study | |
| JP2020500864A5 (https=) | ||
| Vis et al. | Risk of disease flare with LHRH agonist therapy in men with prostate cancer: myth or fact? | |
| JP2025159082A (ja) | ホットフラッシュの新規処置法 | |
| Shetty et al. | Lesion sterilization and tissue repair in primary teeth | |
| Hyer et al. | Early and late toxicity of radioiodine therapy: detection and management | |
| Karunakar et al. | Comparative evaluation of efficacy of diclofenac and ketoprofen administered using transdermal drug delivery route in management of post endodontic pain: A randomized controlled clinical trial | |
| Fuller et al. | Postoperative pain management with oral methylprednisolone in symptomatic patients with a pulpal diagnosis of necrosis: a prospective randomized, double-blind study | |
| Sakai et al. | Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer | |
| Ged et al. | Management of castrate-resistant prostate cancer in older men | |
| Kubota et al. | Feasibility of metronomic chemotherapy with tegafur-uracil, cisplatin, and dexamethasone for docetaxel-refractory prostate cancer | |
| Herlofson et al. | Osteonecrosis of the jaw in a patient with bone metastatic prostate cancer after long-term bisphosphonate treatment with severe deterioration following radium-223 | |
| Santiago et al. | Balancing the benefits and risks of low-dose glucocorticoid in rheumatoid arthritis. | |
| Rizzoli | Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis | |
| Borrega et al. | Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer | |
| Karavasilis et al. | Biweekly administration of low-dose docetaxel in hormone-resistant prostate cancer: pilot study of an effective subtoxic therapy |